WHO ICTRP trial
A prospective, randomized, single center, phase II study of Fluzoparib combined…
ChiCTR2000035193 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2000035193 |
|---|---|
| Public title | A prospective, randomized, single center, phase II study of Fluzoparib combined with ADT for high risk localized prostate cancer with homologous recombination repair abnormalities before prostatectomy |
| Scientific title | A prospective, randomized, single center, phase II study of Fluzoparib combined with ADT for high risk localized prostate cancer with homologous recombination repair abnormalities before prostatectomy |
| Primary sponsor | Chinese PLA General Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 2 |
| Countries | China |
| Conditions | high risk localized prostate cancer with homologous recombination repair abnormalities |
| Interventions | experimental group 1:Fluzoparib combined with ADT;experimental group 2:Fluzoparib;control group:ADT |
| Registration date | Aug 2, 2020 |
| Target size | experimental group 1:24;experimental group 2:24;control group:24 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: